Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia

Blood

Volumn 91, Issue 8, 1998, Pages 2713-2721

  Kluin Nelemans, J C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEPHROTOXICITY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION;

EID: 0032522945     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.2713.2713_2713_2721     Document Type: Article

References (23)

1. Sokal JE, Baccarani M, Russe D, Tura S: Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49, 1988
2. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A, Wussow P, Bartram C, Griesshammer M, Bergmann L, Essers U, Falge C, Hochhaus A, Queisser U, Sick C, Meyer P, Schmitz N, Verpoort K, Eimermacher H, Walther F: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398, 1993
3. Bergasagel DE, Haas RH, Messner HA: Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 13:29, 1986
4. Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M: Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69:961, 1987
5. Werter M, Witte de T, Janssen J, Pauw de B, Haanen C: Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia. Results of a multicenter study. Blut 56:209, 1988
6. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 114:532, 1991
7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
8. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hiroshima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906, 1995
9. Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
10. Shepherd PCA, Richards SM, Allan NC: Progress with interferon in CML-Results of the MRC UK CML III study. Bone Marrow Transplant 17:S15, 1996 (suppl 3)
11. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A: Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064. 1994
12. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280, 1987
13. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710, 1983
14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C, Italian Cooperative CML Study Group: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789, 1984
15. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
16. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069, 1996
17. Hasford J, Baccarani M, Hehlmann R, Ansari H, Tura S, Zuffa E: Interferon-α and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-α. Blood 87:5384, 1996
18. Hehlmann R: Chronic myelogenous leukemia: Does interferon alpha prolong life? Leukemia 10:193, 1996
19. Schofield JR, Robinson WA, Murphy JR, Rovira DK: Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736, 1994
20. O'Brien S, Kantarjian H, Talpaz M: Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma 23:247, 1996
21. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR: Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 125:541, 1996
22. CML Trialists' Collaborative Group: Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Nat Cancer Inst 89:1616, 1997
23. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Interferon alpha2b (IFN) and cytarabine (Ara-C) increase survival and cytogenetic response in chronic myeloid leukemia (CML). Results of a randomized trial. N Engl J Med 337:223. 1997